S
Santhera Pharmaceuticals Holding AG
SIX:SANN
Santhera Pharmaceuticals Holding AG
SIX:SANN
Price:
16.8
CHF
0.6%
Market Cap:
CHf244.8m
Relative Value
The Relative Value of one SANN stock under the Base Case scenario is 12.74 CHF. Compared to the current market price of 16.8 CHF, Santhera Pharmaceuticals Holding AG is Overvalued by 24%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SANN
Relative Value
Base Case
12.74
CHF
Overvaluation 24%
S
Multiples Across Competitors
SANN Competitors Multiples
Santhera Pharmaceuticals Holding AG Competitors
Santhera Pharmaceuticals Holding AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
S
|
Santhera Pharmaceuticals Holding AG
SIX:SANN
|
244.8m CHF | 4.8 | -3.6 | -5.1 | -4.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
401.3B USD | 6.6 | 95.9 | 15.7 | 21.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.4B USD | 5.5 | 26.2 | 15 | 15 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.4B USD | 6.3 | 21.7 | 13.5 | 16.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
126.8B USD | 10.6 | 32.1 | 24.3 | 25.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.6B USD | 5.7 | 18.1 | 13.6 | 15.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.7B AUD | 3.2 | 34.9 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.1B EUR | 11.2 | 35.8 | 39 | 39.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
